Quantcast

Industry news that matters to you.  Learn more

NephroCheck Test Aimed at Providing Risk Assessment Information for ICU Patients

Reading time: 2 minutes

Astute Medical, Inc., a developer of biomarker-based diagnostics intended to aid physicians in managing critically ill patients, today revealed its first product candidate, the NephroCheck Test, at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) being held in Brussels, Belgium. The novel test, which will be launched in Europe later this year, is intended to aid in the risk assessment for acute kidney injury (AKI) in critically ill patients, a condition with mortality rates approaching 40 to 80 percent for severely ill patients in intensive care settings (ICU).

“The kidneys serve a vital function in the human body, comparable to that of the heart or lungs,” said Dr. John Kellum, professor of critical care medicine at the University of Pittsburgh School of Medicine. “Up to 20 percent of critically ill patients experience AKI during the course of their illness, which can result in longer hospital stays, long term loss of function and diminished quality of life, and in the most severe cases loss of life.”

“AKI is often a stealth condition, and the assessment of risk can be complicated by a lack of apparent symptoms and co-morbidities,” said Chris Hibberd, Astute Medical chief executive officer. “By providing information relative to risk, we believe the NephroCheck Test can potentially help improve patient management.”

The NephroCheck Test utilizes immunoassay technology to identify changes in biomarker measurements that correlate with risk for AKI. The test is performed on a small cartridge that employs proprietary microfludic engineering to conduct most sample processing steps. Biomarker measurements are read by the Astute140 Meter, which delivers results in about 20 minutes.

Astute Medical utilized its proprietary research platform to identify and validate biomarkers used in the NephroCheck Test. After assessing target candidates, researchers performed a series of validation studies to identify the most promising biomarker targets.

The Astute140 Meter and the NephroCheck Test are not available in the United States.

Source: PR Newswire